CD63 and non-small cell lung carcinoma: Similarly, Koh’s study [37] identified CD63 as a prognostic marker for non-small-cell lung cancer (NSCLC), suggesting that low CD63 expression might serve as an adverse prognostic factor for NSCLC patients.